Get the Stockscreener App
3.89
13.08%
0.45
Pre-market:
3.99
0.10
+2.57%
iBio Inc stock is traded at $3.89, with a volume of 2.16M.
It is up +13.08% in the last 24 hours and up +26.71% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$3.44
Open:
$3.41
24h Volume:
2.16M
Relative Volume:
9.64
Market Cap:
$38.41M
Revenue:
$2.05M
Net Income/Loss:
$-23.15M
P/E Ratio:
-0.5866
EPS:
-6.6319
Net Cash Flow:
$-16.93M
1W Performance:
+5.71%
1M Performance:
+26.71%
6M Performance:
+91.63%
1Y Performance:
+224.17%
1-Day Range:
$3.41
$4.37
1-Week Range:
$3.35
$4.37
52-Week Range:
$1.05
$4.98
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
3.89 | 38.41M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
iBio, Inc. Advances in Therapeutics and Leadership - TipRanks
iBio Inc. stock falls Friday, underperforms market - MarketWatch
iBio Inc. stock falls Thursday, underperforms market - MarketWatch
iBio to Begin Trading on the Nasdaq Stock Exchange - GlobeNewswire
iBio Inc. stock rises Wednesday, outperforms market - MarketWatch
iBio Announces Transfer to Nasdaq Capital Market - TipRanks
Can iBio's Nasdaq Move Transform Its Market Presence? Key Details Revealed - StockTitan
Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year? - Insider Monkey
10 Stocks Insiders Are Buying This Year - Insider Monkey
Ibio Inc Faces Financial Risk from Potential Stockholder Equity Dilution and Capital Raising Challenges - TipRanks
iBio Inc. stock falls Tuesday, underperforms market - MarketWatch
SEC Form 424B3 filed by iBio Inc. - Quantisnow
iBio Inc. stock falls Monday, underperforms market - MarketWatch
iBio Inc. (IBIO) reports earnings - Quartz
iBio, Inc. Reports Second Quarter Fiscal 2025 Financial Results and Corporate Updates on Advancements in Cardiometabolic Therapeutics - Nasdaq
iBio Reports Fiscal Second Quarter 2025 Financial Results - GlobeNewswire
IBIO's Strategic Pivot: AI-Powered Antibody Discovery Shows Promise Despite Q2 Losses - StockTitan
iBio Inc. stock rises Friday, outperforms market - MarketWatch
A Tale of Resilience: iBio Inc Amid Stock Market Turbulence - The InvestChronicle
iBio (IBIO) Projected to Post Quarterly Earnings on Friday - Defense World
iBio Inc. stock rises Thursday, outperforms market - MarketWatch
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
iBio (NYSE:IBIO) Trading Up 4% – Time to Buy? - Defense World
iBio (NYSEMKT:IBIO) Trading Up 1.3% – Still a Buy? - Defense World
iBio Inc. stock rises Monday, outperforms market - MarketWatch
iBio Inc. stock falls Monday, still outperforms market - MarketWatch
I: Weekly TechBio News - substack.com
iBio Announces Successful Closing of Private Placement OfferingOn January 10, 2025, iBio, Inc. (NYSE American: IBIO) announced the completion of a private placement offering, marking an important development for the company. The securities purchase a - Defense World
iBio director William Clark purchases $4,999 in common stock - Investing.com India
iBio director Parada acquires $499,998 in common stock By Investing.com - Investing.com Australia
iBio director William Clark purchases $4,999 in common stock By Investing.com - Investing.com Australia
Felipe Duran Increases Stake in iBio Inc with Recent Share Purch - GuruFocus.com
Director David Arkowitz Acquires 18,382 Shares of iBio Inc (IBIO) - GuruFocus.com
Insider Buying: Gary Sender Acquires 9,191 Shares of iBio Inc (I - GuruFocus.com
Ibio's chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Australia
iBio director Gary Sender purchases $24,999 in common stock By Investing.com - Investing.com Australia
Ibio CEO Brenner Martin acquires $24,999 in stock By Investing.com - Investing.com Australia
Ibio's CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Australia
iBio director Arkowitz purchases $49,999 in common stock By Investing.com - Investing.com Australia
Ibio’s CFO Duran Felipe buys $24,999 in common stock By Investing.com - Investing.com Nigeria
Ibio’s chief legal officer Marc Banjak buys $24,999 in stock By Investing.com - Investing.com Nigeria
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):